Jane Street Group LLC Has $695,000 Position in Mesoblast Limited (NASDAQ:MESO)

Jane Street Group LLC raised its stake in shares of Mesoblast Limited (NASDAQ:MESO) by 46.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 85,102 shares of the company’s stock after acquiring an additional 26,959 shares during the quarter. Jane Street Group LLC owned approximately 0.07% of Mesoblast worth $695,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC boosted its position in Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after buying an additional 3,099 shares in the last quarter. Perkins Coie Trust Co raised its stake in shares of Mesoblast by 15.0% in the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after acquiring an additional 1,500 shares during the last quarter. Rathbones Group PLC acquired a new position in shares of Mesoblast in the 2nd quarter worth approximately $95,000. XTX Topco Ltd bought a new stake in Mesoblast during the 2nd quarter worth approximately $103,000. Finally, Creative Planning bought a new stake in Mesoblast during the 3rd quarter worth approximately $147,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Analysts Set New Price Targets

MESO has been the topic of a number of recent analyst reports. Piper Sandler boosted their price objective on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research note on Thursday, December 19th. Jefferies Financial Group cut shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Finally, Maxim Group raised Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $13.50.

Mesoblast Price Performance

MESO opened at $20.12 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The company’s 50 day moving average is $12.36 and its 200-day moving average is $9.09. Mesoblast Limited has a 1-year low of $1.61 and a 1-year high of $22.00.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.